OVERVIEW

Community Oncologists’ Role in Selecting Optimal Oral Selective Estrogen Receptor Degraders (SERDs) Treatment for HR+/HER2- Breast Cancer is organized by Physicians' Education Resource, LLC (PER), Association of Cancer Care Centers (ACCC), Oncology State Society Network (OSSN) and will be held on Mar 26, 2025.

Description:
This live, virtual symposium will bring together a world-renowned expert in the management of breast cancer with a local community oncologist to discuss the role of next-generation selective estrogen receptor degraders (SERDs) in the treatment of hormone receptor–positive, HER2-negative (HR+/HER2-) breast cancer. In this program, the faculty will review recent clinical updates evaluating SERDs for metastatic HR+/HER2- breast cancer and discuss best practices to implement biomarker testing to guide treatment decisions. Case-based conversations will be included throughout the program to provide clinicians with the key takeaways of all the data. Participants will have the opportunity to reflect on how experts make clinical decisions with regards to initiating and sequencing therapy, as well as best practices in managing adverse events.

Learning Objectives:
Upon completion of this activity, participants will be able to:

Develop biomarker-based diagnostic approaches to assess HR+/HER2- MBC progression and identify optimal treatment options
Assess clinical trial data for current and emerging agents for HR+/HER2- MBC and impact on the treatment paradigm for treatment plans
Implement shared decision-making strategies to optimize AE management and enhance treatment adherence in clinical practice